Home Cart 0 Sign in  
X

[ CAS No. 1703-07-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1703-07-7
Chemical Structure| 1703-07-7
Chemical Structure| 1703-07-7
Structure of 1703-07-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1703-07-7 ]

Related Doc. of [ 1703-07-7 ]

Alternatived Products of [ 1703-07-7 ]

Product Details of [ 1703-07-7 ]

CAS No. :1703-07-7 MDL No. :MFCD04971427
Formula : C5H5ClN2O Boiling Point : -
Linear Structure Formula :- InChI Key :UGDOVAWXAHZLEV-UHFFFAOYSA-N
M.W : 144.56 Pubchem ID :164871
Synonyms :

Calculated chemistry of [ 1703-07-7 ]

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.2
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 34.83
TPSA : 45.75 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.68 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.25
Log Po/w (XLOGP3) : 0.71
Log Po/w (WLOGP) : 0.73
Log Po/w (MLOGP) : 0.79
Log Po/w (SILICOS-IT) : 2.17
Consensus Log Po/w : 1.13

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.68
Solubility : 3.04 mg/ml ; 0.021 mol/l
Class : Very soluble
Log S (Ali) : -1.25
Solubility : 8.15 mg/ml ; 0.0564 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.54
Solubility : 0.418 mg/ml ; 0.00289 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.93

Safety of [ 1703-07-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1703-07-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1703-07-7 ]
  • Downstream synthetic route of [ 1703-07-7 ]

[ 1703-07-7 ] Synthesis Path-Upstream   1~7

  • 1
  • [ 1703-07-7 ]
  • [ 54709-94-3 ]
Reference: [1] Pharmaceutical Bulletin, 1957, vol. 5, p. 229,233
[2] Yakugaku Zasshi, 1962, vol. 82, p. 304,307[3] Chem.Abstr., 1963, vol. 58, # 3427,
  • 2
  • [ 19064-64-3 ]
  • [ 1834-27-1 ]
  • [ 1703-07-7 ]
YieldReaction ConditionsOperation in experiment
18%
Stage #1: at 110 - 115℃; for 3 h;
Stage #2: With sodium hydrogencarbonate In water
3,6-Dichloro-4-methylpyridazine (30.6 g, 190 mmol) was suspended in glacial AcOH (800 mL) at ambient temperature and heated in an oil bath thermostatted at 110-115 °C for 3 h. (The mixture became homogenous after 1 h.) The mixture was allowed to cool and the AcOH was removed by vacuum distillation. The resulting solid residue was slowly treated with sat. NaHCO3 solution (200 mL) to give a pale yellow heterogenous mixture that was adjusted to pH 6 by the slow addition of solid NaHCO3 with vigorous stirring. The mixture was extracted with dichloromethane (2 x 250 mL) and the combined organic phase was washed with sat. NaCl solution (60 mL), dried (MgSO4) and evaporated to afford a solid (20.9 g). The crude material was subjected to column chromatography (gradient 1percent MeOH/CH2Cl2 to 5percent MeOH/CH2Cl2) to afford, 6-chloro-4-methyl-2H-pyridazin-3-one (13.4 g, 92.7 mmol; 49percent) [Rf 0.21 (2.5percent MeOH/CH2Cl2)] and 6-chloro-5-methyl-2H-pyridazin-3-one (5.00 g, 34.6 mmol; 18percent) [Rf 0.11 (2.5percent MeOH/CH2Cl2)] as a colourless solids. 6-Chloro-4-methyl-2H-pyridazin-3-one: 1H NMR (200 MHz, CDCl3-CD3OD): 2.12 (3H, s), 3.55 (1H, brs), 7.05 (1H, s); 13C NMR (50 MHz, CDCl3): 16.1 (CH3), 131.7 (CH-5), 139.0 (C-6), 143.0 (C-4), 161.9 (C-3). 6-Chloro-5-methyl-2H-pyridazin-3-one: mp 172-173 °C (from CH2Cl2/light petrol); 1H NMR (200 MHz, CDCl3) δ 2.20 (3H, d, J = 1.3 Hz), 7.13 (1H, q, J = 1.3 Hz); 13C NMR (50 MHz, CDCl3) 16.3 (CH3), 131.9 (CH-5), 139.2 (C-4), 143.2 (C-6), 161.9 (C-3). LRMS (EI): 144 ([M+]). Anal. calcd for C5H5ClN2O: C, 41.54; H, 3.49; N, 19.38. Found: C, 41.55; H, 3.51; N, 19.22.
46%
Stage #1: for 2 h; Reflux
Stage #2: With acetic acid In water
Intermediate VII6-Chloro-4-methyl-2H-pyridazin-3-one and 6-chloro-5-methyl-2H-pyridazin-3-one A suspension of 3,6-dichloro-4-methylpyridazine (6.60 g) in 3.3 M aqueous NaOH solution (66 mL) was stirred at reflux temperature for 2 h. The heating bath was removed and 50percent aqueous acetic acid (25 mL) was added. The aqueous solution was adjusted to pH value 6 and the precipitate formed thereafter was separated by filtration and washed with little water. The precipitate was chromatographed on silica gel (cyclohexane/ethyl acetate 90:10->0:100) to separate the two title compounds.6-Chloro-4-methyl-2H-pyridazin-3-one: Yield: 2.70 g (46percent of theory). Mass spectrum (ESI+): m/z=145/147 (Cl) [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 2.06 (d, J=1.3 Hz, 3H), 7.44 (incompletely resolved q, J=1.3 Hz, 1H), 13.03 (broad s, 1H).6-Chloro-5-methyl-2H-pyridazin-3-one: Yield: 1.90 g (32percent of theory). Mass spectrum (ESI+): m/z=145/147 (Cl) [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 2.19 (d, J=1.3 Hz, 3H), 6.91 (incompletely resolved q, J=1.3 Hz, 1H), 13.02 (broad s, 1H).
Reference: [1] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 5, p. 1644 - 1658
[2] Patent: US2012/108578, 2012, A1, . Location in patent: Page/Page column 26
[3] Acta Chemica Scandinavica (1947-1973), 1961, vol. 15, p. 1660,1665
[4] Pharmaceutical Bulletin, 1957, vol. 6, p. 587,589
[5] Pharmaceutical Bulletin, 1957, vol. 5, p. 229,233
  • 3
  • [ 19064-64-3 ]
  • [ 1834-27-1 ]
  • [ 1703-07-7 ]
YieldReaction ConditionsOperation in experiment
18%
Stage #1: at 110 - 115℃; for 3 h;
Stage #2: With sodium hydrogencarbonate In water
3,6-Dichloro-4-methylpyridazine (30.6 g, 190 mmol) was suspended in glacial AcOH (800 mL) at ambient temperature and heated in an oil bath thermostatted at 110-115 °C for 3 h. (The mixture became homogenous after 1 h.) The mixture was allowed to cool and the AcOH was removed by vacuum distillation. The resulting solid residue was slowly treated with sat. NaHCO3 solution (200 mL) to give a pale yellow heterogenous mixture that was adjusted to pH 6 by the slow addition of solid NaHCO3 with vigorous stirring. The mixture was extracted with dichloromethane (2 x 250 mL) and the combined organic phase was washed with sat. NaCl solution (60 mL), dried (MgSO4) and evaporated to afford a solid (20.9 g). The crude material was subjected to column chromatography (gradient 1percent MeOH/CH2Cl2 to 5percent MeOH/CH2Cl2) to afford, 6-chloro-4-methyl-2H-pyridazin-3-one (13.4 g, 92.7 mmol; 49percent) [Rf 0.21 (2.5percent MeOH/CH2Cl2)] and 6-chloro-5-methyl-2H-pyridazin-3-one (5.00 g, 34.6 mmol; 18percent) [Rf 0.11 (2.5percent MeOH/CH2Cl2)] as a colourless solids. 6-Chloro-4-methyl-2H-pyridazin-3-one: 1H NMR (200 MHz, CDCl3-CD3OD): 2.12 (3H, s), 3.55 (1H, brs), 7.05 (1H, s); 13C NMR (50 MHz, CDCl3): 16.1 (CH3), 131.7 (CH-5), 139.0 (C-6), 143.0 (C-4), 161.9 (C-3). 6-Chloro-5-methyl-2H-pyridazin-3-one: mp 172-173 °C (from CH2Cl2/light petrol); 1H NMR (200 MHz, CDCl3) δ 2.20 (3H, d, J = 1.3 Hz), 7.13 (1H, q, J = 1.3 Hz); 13C NMR (50 MHz, CDCl3) 16.3 (CH3), 131.9 (CH-5), 139.2 (C-4), 143.2 (C-6), 161.9 (C-3). LRMS (EI): 144 ([M+]). Anal. calcd for C5H5ClN2O: C, 41.54; H, 3.49; N, 19.38. Found: C, 41.55; H, 3.51; N, 19.22.
46%
Stage #1: for 2 h; Reflux
Stage #2: With acetic acid In water
Intermediate VII6-Chloro-4-methyl-2H-pyridazin-3-one and 6-chloro-5-methyl-2H-pyridazin-3-one A suspension of 3,6-dichloro-4-methylpyridazine (6.60 g) in 3.3 M aqueous NaOH solution (66 mL) was stirred at reflux temperature for 2 h. The heating bath was removed and 50percent aqueous acetic acid (25 mL) was added. The aqueous solution was adjusted to pH value 6 and the precipitate formed thereafter was separated by filtration and washed with little water. The precipitate was chromatographed on silica gel (cyclohexane/ethyl acetate 90:10->0:100) to separate the two title compounds.6-Chloro-4-methyl-2H-pyridazin-3-one: Yield: 2.70 g (46percent of theory). Mass spectrum (ESI+): m/z=145/147 (Cl) [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 2.06 (d, J=1.3 Hz, 3H), 7.44 (incompletely resolved q, J=1.3 Hz, 1H), 13.03 (broad s, 1H).6-Chloro-5-methyl-2H-pyridazin-3-one: Yield: 1.90 g (32percent of theory). Mass spectrum (ESI+): m/z=145/147 (Cl) [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 2.19 (d, J=1.3 Hz, 3H), 6.91 (incompletely resolved q, J=1.3 Hz, 1H), 13.02 (broad s, 1H).
Reference: [1] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 5, p. 1644 - 1658
[2] Patent: US2012/108578, 2012, A1, . Location in patent: Page/Page column 26
[3] Acta Chemica Scandinavica (1947-1973), 1961, vol. 15, p. 1660,1665
[4] Pharmaceutical Bulletin, 1957, vol. 6, p. 587,589
[5] Pharmaceutical Bulletin, 1957, vol. 5, p. 229,233
  • 4
  • [ 19064-64-3 ]
  • [ 1703-07-7 ]
Reference: [1] Yakugaku Zasshi, 1962, vol. 82, p. 304,307[2] Chem.Abstr., 1963, vol. 58, # 3427,
[3] Yakugaku Zasshi, 1962, vol. 82, p. 1005,1009[4] Chem.Abstr., 1963, vol. 58, # 4559,
[5] Patent: EP2168959, 2010, A1, . Location in patent: Page/Page column 112
[6] Patent: US2008/207902, 2008, A1, . Location in patent: Page/Page column 62
  • 5
  • [ 89466-36-4 ]
  • [ 1703-07-7 ]
Reference: [1] Yakugaku Zasshi, 1962, vol. 82, p. 1005,1009[2] Chem.Abstr., 1963, vol. 58, # 4559,
[3] Yakugaku Zasshi, 1962, vol. 82, p. 304,307[4] Chem.Abstr., 1963, vol. 58, # 3427,
  • 6
  • [ 616-02-4 ]
  • [ 1703-07-7 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 5, p. 1644 - 1658
  • 7
  • [ 5754-18-7 ]
  • [ 1703-07-7 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 5, p. 1644 - 1658
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1703-07-7 ]

Chlorides

Chemical Structure| 19064-67-6

[ 19064-67-6 ]

6-Chloro-3-hydroxypyridazine

Similarity: 0.88

Chemical Structure| 1114563-59-5

[ 1114563-59-5 ]

6-Chloro-2,5-dimethylpyridazin-3(2H)-one

Similarity: 0.85

Chemical Structure| 1834-27-1

[ 1834-27-1 ]

6-Chloro-4-methylpyridazin-3(2H)-one

Similarity: 0.84

Chemical Structure| 61404-49-7

[ 61404-49-7 ]

6-Chloro-4-ethylpyridazin-3(2H)-one

Similarity: 0.77

Chemical Structure| 17285-36-8

[ 17285-36-8 ]

5,6-Dichloropyridazin-3(2H)-one

Similarity: 0.73

Amides

Chemical Structure| 19064-67-6

[ 19064-67-6 ]

6-Chloro-3-hydroxypyridazine

Similarity: 0.88

Chemical Structure| 1114563-59-5

[ 1114563-59-5 ]

6-Chloro-2,5-dimethylpyridazin-3(2H)-one

Similarity: 0.85

Chemical Structure| 1834-27-1

[ 1834-27-1 ]

6-Chloro-4-methylpyridazin-3(2H)-one

Similarity: 0.84

Chemical Structure| 61404-49-7

[ 61404-49-7 ]

6-Chloro-4-ethylpyridazin-3(2H)-one

Similarity: 0.77

Chemical Structure| 54709-94-3

[ 54709-94-3 ]

5-Methylpyridazin-3(2H)-one

Similarity: 0.73

Related Parent Nucleus of
[ 1703-07-7 ]

Pyridazines

Chemical Structure| 19064-67-6

[ 19064-67-6 ]

6-Chloro-3-hydroxypyridazine

Similarity: 0.88

Chemical Structure| 1114563-59-5

[ 1114563-59-5 ]

6-Chloro-2,5-dimethylpyridazin-3(2H)-one

Similarity: 0.85

Chemical Structure| 1834-27-1

[ 1834-27-1 ]

6-Chloro-4-methylpyridazin-3(2H)-one

Similarity: 0.84

Chemical Structure| 61404-49-7

[ 61404-49-7 ]

6-Chloro-4-ethylpyridazin-3(2H)-one

Similarity: 0.77

Chemical Structure| 54709-94-3

[ 54709-94-3 ]

5-Methylpyridazin-3(2H)-one

Similarity: 0.73